(AOF) – A global medical device company, Mauna Kea Technologies announces that its net loss amounted to 11.1 million euros as of December 31, 2022, down 2.26 million euros compared to the previous financial year. Its operating loss has decreased but remains negative, standing at 9.06 million euros compared to 12.21 million euros at the end of 2021. Its total turnover amounts to 7.47 million euros, in withdrawal of 3% over one year. The 2022 gross margin rate stood at 73.3%, almost stable compared to 74.2% at the end of 2021 (-87 points).
This gross margin rate is supported by the still favorable sales mix in 2022, despite the problems related to supplies and inflation during the year.
In addition, the group announces a cash position of €3.1 million as of December 31, 2022 and €9.1 million as of January 26, 2023, following receipt of the first payment from the joint venture with Tasly.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.